三七脂肝丸治疗非酒精性脂肪肝肝功能异常59例

罗丹; 江玉

doi:10.11653/syfj2014050202

您当前的位置：

首页 >

文章列表页 >

三七脂肝丸治疗非酒精性脂肪肝肝功能异常59例

更新时间：2024-01-04

- 三七脂肝丸治疗非酒精性脂肪肝肝功能异常59例
- Sanqi Zhigan Pill Treat Non-alcoholic Fatty Liver Disease of Abnormal Liver Function Patients 59 Cases
- 中国实验方剂学杂志 2014年20卷第5期页码：202-205
- 作者机构：
- 作者简介：
- 基金信息：
  
  四川省教育厅项目（川教函[2011]538号11ZB130）
- DOI：10.11653/syfj2014050202
  中图分类号：
- 纸质出版日期：2014
- 稿件说明：
移动端阅览
罗丹, 江玉. 三七脂肝丸治疗非酒精性脂肪肝肝功能异常59例[J]. 中国实验方剂学杂志, 2014,20(5):202-205.

LUO Dan, JIANG Yu. Sanqi Zhigan Pill Treat Non-alcoholic Fatty Liver Disease of Abnormal Liver Function Patients 59 Cases[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(5): 202-205.
罗丹, 江玉. 三七脂肝丸治疗非酒精性脂肪肝肝功能异常59例[J]. 中国实验方剂学杂志, 2014,20(5):202-205. DOI： 10.11653/syfj2014050202.

LUO Dan, JIANG Yu. Sanqi Zhigan Pill Treat Non-alcoholic Fatty Liver Disease of Abnormal Liver Function Patients 59 Cases[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(5): 202-205. DOI： 10.11653/syfj2014050202.

摘要

目的：探讨三七脂肝丸治疗肝功能异常非酒精性脂肪肝（NAFLD）的临床疗效及作用机制。方法：将116例患者随机按数字法分为对照组57例和观察组59例。两组均参照“非酒精性脂肪性肝病诊疗指南”进行非药物干预，对照组服用多烯磷脂酰胆碱胶囊，2粒/次，3次/d，口服，还原型谷胱甘肽片200 mg/次，3次/d，口服。观察组服用三七脂肝丸，5 g/次，3次/d，口服。两组疗程均为12周。监测丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、甘油三酯（TG）、总胆固醇（TC）、高密度脂蛋白胆固醇（HDL-C）及低密度脂蛋白胆固醇（LDL-C）；治疗前后肝脾B超检查；测定血清超氧化物歧化酶（SOD）、肿瘤坏死因子-α（TNF-α）和白细胞介素-18（IL-18）水平。结果：治疗后疗效观察组总有效率93.22%优于对照组的77.19%（P<0.05）；治疗后两组ALT，AST较治疗前明显好转（P<0.01），两组ALT，AST复常率相当；观察组TC，TG，LDL-C和HDL-C复常率优于对照组；两组治疗后B超检查脂肪肝程度均有好转，观察组的好转程度优于对照组（P<0.05）；治疗后两组患者血清SOD均较治疗前升高，治疗后观察组高于对照组（P<0.05）；治疗后两组血清TNF-α和IL-18水平均治疗前下降，观察组低于对照组（P<0.05）。结论：三七脂肝丸对肝功能异常NAFLD患者的肝功能有保护作用，能促使患者血脂好转，其作用机制可能与升高患者血清SOD水平，降低TNF-α和IL-18水平与有关。

Abstract

Objective: The discuss clinical effects and mode of Sanqi Zhigan pill on non-alcoholic fatty liver disease(NAFLD) of 59 cases abnormal liver function patients. Method: One hundred and sixteen cases of patients were randomly divided into control group (57 cases) and observation group (59 cases) by digital method. The both groups were meddled with non-drug referred to clinical practice guideline of non-alcoholic fatty liver disease.The patients in control group took polyene phosphatidyl choline capsule

2 pieces/time

3 times/day

orally.Reduced glutathione tablets

200 mg/time

3 times/day

orally.For patients in observation group

they took Sanqi Zhigan pill

5 g/time

3 times/day

orally.The treatment course was 12 weeks for both groups.Monitor alanine aminotransferase (ALT)

glutamic oxalacetic transaminase(AST)

triglyceride(TG)

total cholesterol(TC)

high density lipoprotein cholesterol(HDL-C) and low density lipoprotein cholesterin (LDL-C).Examine liver and spleen B ultrasound before and after treatment.Measure the level of serum superoxide dismutase (SOD)

tumor necrosis factor alpha(TNF-α) and interleukin-18(IL-18). Result: After the treatment

total effective rate of the observation group was 93.22%

superior to 77.19% of the control group(P<0.05).After the treatment

ALT

AST of both groups improved markedly(P<0.01)

after often rate of ALT

AST in the two groups were fairly.Often rate of TC

LDL-C and HDL-C in observation group were better than control group.B ultrasonic examined the degree of fatty liver better in both group after the treatment.Improvement of the observation group level was superior to the control group(P<0.05)

patients in two groups got a higher serum SOD after the treatment.Observation group level was higher than the control group(P<0.05)

the level of serum TNF-α and IL-18 got declined.Observation group is lower than the control group(P<0.05). Conclusion: Sanqi Zhigan pill can protect patients' liver function with abnormal liver NAFLD function.Besides improve blood lipid back to normal.Its mode of action may be related to elevate serum SOD level

lower TNF-α and IL-18.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

超氧化物歧化酶参与肝损伤的研究进展

参葛方防治大鼠非酒精性脂肪肝的实验研究

EGCG抗糖尿病心肌病小鼠心肌组织中氧化应激损伤作用机制的探讨

药食同源保肝中药的抗炎抗氧化作用

基于胆固醇代谢的复方甘草酸苷片配伍雷公藤多苷片减轻肝损伤机制